Drug Master File

Document in the pharmaceutical industry

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)

This article needs attention from an expert in Pharmacology. Please add a reason or a talk parameter to this template to explain the issue with the article. WikiProject Pharmacology may be able to help recruit an expert. (May 2009)

|

This article may be confusing or unclear to readers. Please help clarify the article. There might be a discussion about this on the talk page. (May 2009) (Learn how and when to remove this message)

|

This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (May 2009) (Learn how and when to remove this message)

|

(Learn how and when to remove this message)

Drug Master File or DMF is a document prepared by a pharmaceutical manufacturer and submitted solely at its discretion to the appropriate regulatory authority in the intended drug market. There is no regulatory requirement to file a DMF. However, the document provides the regulatory authority with confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. Typically, a DMF is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its intellectual property from its partner while complying with regulatory requirements for disclosure of processing details.

## Description

[edit]

Drug Master File (DMF) is a document containing complete information on an Active Pharmaceutical Ingredient (API) or finished drug dosage form. It is known as European Drug Master File (EDMF) or Active Substance Master File (ASMF) and US-Drug Master file (US-DMF) in Europe and United States respectively.

## DMFs in the United States

[edit]

In the United States, DMFs are submitted to the Food and Drug Administration (FDA). The Main Objective of the DMF is to support regulatory requirements and to prove the quality, safety and efficacy of the medicinal product for obtaining an Investigational New Drug Application (IND), a New Drug Application (NDA),As an Abbreviated New Drug Application (ANDA), another DMF, or an Export Application.

In United States there are 5 types of Drug Master file:[1]

* Type I Manufacturing Site, Facilities, Operating Procedures and Personnel

* Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product

* Type III Packaging Material

* Type IV Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation

* Type V FDA Accepted Reference Information

## DMFs in Europe

[edit]

The content and the format for drug master file used in United States differs from that used in European Countries to obtain market authorization (MA). The Main Objective of the EDMF is to support regulatory requirements of a medicinal product to prove its quality, safety and efficacy. This helps to obtain a Marketing Authorisation grant.

## References

[edit]

1. ^ "Guideline for Drug Master Files". US Food and Drug Administration. Archived from the original on June 14, 2009. Retrieved 2009-09-19.

## External links

[edit]

* FDA: Guideline for drug master files
* [1]
* DMF search engine
* Draft Note for Guidance on the EDMF procedure[permanent dead link]